Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
RESEARCH TOOLSreports
Holding PVLA?
Track your performance easily
PVLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.20 - $22.32
Previous CloseN/A
Volume11.83K
Average Volume (3M)36.34K
Market Cap
$148.35M
Enterprise Value-$954.53K
Total Cash (Recent Filing)$29.36M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.61
Shares Outstanding11,221,307
10 Day Avg. Volume43,446
30 Day Avg. Volume36,336
Standard Deviation0.25
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.18
Price to Cash Flow (P/CF)29.90
P/FCF Ratio29.90
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$34.00Price Target Upside157.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Options Prices
Currently, No data available
---
Ownership Overview
3.52% Insiders
0.26% Mutual Funds
― Other Institutional Investors
96.12% Public Companies and Individual Investors
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $6.20 and its highest was $22.32 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $148.35M.
When is Palvella Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Mar 27, 2024. The company reported -$3.706 earnings per share for the quarter, beating the consensus estimate of -$9.6 by $5.894.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 11,221,307 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$3.706 in its last earnings report, beating expectations of -$9.6. Following the earnings report the stock price went up 0.906%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
---
Palvella Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (157.97% Upside)
$34.00 (157.97% Upside)
Hedge Fund Trend
Decreased
By 12.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.45%
12-Months-Change
Fundamentals
Return on Equity
-68.21%
Trailing 12-Months
Asset Growth
-65.44%
Trailing 12-Months
Company Description
Palvella Therapeutics
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
---
PVLA Earnings Call
Q1 2023
0:00 / 0:00
---
PVLA Stock 12 Month Forecast
Average Price Target
$34.00
▲(157.97% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Gritstone bio
―
Eton Pharmaceuticals
―
Karyopharm Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering PVLA
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+8.85%
reiterated a buy rating 11 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +8.85% per trade.
---